Loading…
← CockpitCompetitor Analysis › PNTG Pennant Group IncOpen in the cockpit ↗

Pennant Group IncPNTGCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical/Nursing Services

Operator of home health, hospice and senior living services through an independent, locally-managed operating model.

Momentum neutral 43
Mkt cap
$1.26B
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$19.0M
20-day average traded
Fwd P/E
23.7×
forward earnings
ROIC−WACC
-3.6 pp
WACC 10.0%
Hurdle
+1 pp
Req g minus delivered
Next earnings
105 days
3 Mar 2027
Close · USD$35.81
1D-1.9%
1W-2.7%
1M-13.7%
3M-8.2%
6M+1.4%
YTD+27.2%
1Y+41.0%
ATR %5.5%
Beta0.37
52w lowhigh19.1% off high

What Pennant does

Operator of home health, hospice and senior living services through an independent, locally-managed operating model.

Paid mostly by Medicare, which sets fixed payment rates per 30-day period of home health care and per day of hospice care, so government rate-setting matters. Home health and hospice carry the business, with senior living paid privately by residents. It was spun off from Ensign Group in 2019.

Products and services

  • Home health services
  • Hospice care
  • Senior living communities

Customers

  • Seniors needing home health/hospice care
  • Medicare/Medicaid programs

Where it sits in the supply chain

  • Health care services
  • Home health, hospice & senior living
  • Independent local operating-company…

What could go right

  • Aging population home health/hospice demand
  • M&A/de novo growth strategy

What could go wrong

  • Medicare/Medicaid reimbursement rate risk
  • Labor cost/staffing shortages

Moat: narrow (distribution, scale). Decentralized local-leadership model drives operational focus, though scale remains smaller than national peers.

Headquarters: Eagle, Idaho · Founded: 2019 · Employees: 9,700

Named competitors

Pennant at a glance

Size Pennant (PNTG) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.26B, the 2087th largest of 3,085 United States companies the cockpit tracks. Shares closed at $35.81 on 18 Nov 2026.

Performance Over six months the shares gained 1.4%, against +17.1% for the median peer and -2.2% for the United States market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue grew 38.7% over the last twelve months (peer median +7.9%); the operating margin is 6.2% (peer median 3.5%).

Valuation It trades at 23.7× forward earnings against a peer median of 29.4× (7th cheapest of 16).

Price implies For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.6 points below its cost of capital (10.0% WACC).

Short interest Short interest is 3.3% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 117PNTG 104
Six months, rebased to 100: Pennant against the median of its 20 peers (local-currency closes).

Pennant financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.17B$948M$695M$545M$473M
Revenue growth—+36%+28%+15%—
Gross profit$153M$122M$87.6M$61.9M$53.7M
EBITDA$85.1M$65.6M$44.3M$30.8M$25.4M
Net income$35.9M$29.6M$22.6M$13.4M$6.64M
Free cash flow$18.7M$26.3M$15.0M$25.0M-$5.13M
Capital expenditure$45.8M$22.0M$20.4M$8.11M$14.2M
Total debt$489M$460M$273M$330M$327M

Quarterly statements and history in the cockpit →

Pennant competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%OPKMETROPOLISDIACLARINUTXLMRI1833GDRXUSPH4544TDOCAGLWGS688315AHCOAMBEASNDAPSNLREGVIJAYAPNTG6-month return →1-month return →
Up and to the right = strong over both horizons. Pennant is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×60×METROPOLISDIACLARINUTXLMRI1833GDRXUSPH4544AGLWGS688315AMBEAREGVIJAYAPNTGRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Pennant is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%METROPOLISDIACLARINUTXUSPHTDOCPNTGGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Pennant is the large dot.

Pennant competitors and peer comparison

Head to head with its named competitors (PNTG vs ADUS vs BKD vs EHC)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Pennant PNTG$1.26B+1%+39%6%23.7×20.7%
Addus HomeCare ADUS$2.25B+29%+12%11%16.2×4.0%
Brookdale Senior Living BKD$2.06B-36%-8%6%482.6×19.3%
Encompass Health EHC$13.2B+27%+9%18%20.1×5.7%

How Pennant compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Pennant against its 20 peers (data as of 18 Nov 2026)
MeasurePNTGPeer medianRank in peer set
1-month return-13.7%+1.3%2nd lowest of 21
6-month return+1.4%+17.1%7th lowest of 21
Distance from 52-week high-19.1%-23.8%9th highest of 21
Revenue growth (TTM)+38.7%+7.9%2nd highest of 21
Operating margin6.2%3.5%9th highest of 21
Forward P/E23.7×29.4×7th cheapest of 16
Growth the price implies (Req g, 7 yrs)20.7%8.5%3rd most demanding of 15
Growth delivered (Del g)+19.4%+11.8%3rd highest of 15
Hurdle (Req g minus delivered)+1.4 pp-0.4 pp7th most demanding of 15
ROIC minus cost of capital-3.6 pp-3.6 pp10th highest of 19
EV / EBITDA20.8×10.1×5th most expensive of 15
Net debt / EBITDA5.5×1.3×4th most indebted of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Pennant PNTGUnited States$1.26B+1%+39%6%23.7×20.7%+19.4%
OPKO Health OPKUnited States$1.25B+37%-22%-29%n/an/an/a
Metropolis Healthcare METROPOLIS.NSIndia$1.25B+11%+20%18%44.5×32.4%+10.5%
Diagnostyka DIA.WAPoland$1.28B-6%+19%15%19.5×7.3%+18.9%
Clariane CLARI.PAFrance$1.32B-20%+1%6%8.2×6.8%+6.5%
Nutex Health NUTXUnited States$1.19B+42%-19%39%6.5×-18.0%+253.5%
Lumexa Imaging LMRIUnited States$1.35B+89%+8%2%16.0×n/an/a
Ping An Healthcare and Technology 1833.HKHong Kong$1.36B-47%+8%3%33.5×3.5%-5.1%
GoodRx GDRXUnited States$1.15B+33%-2%12%10.6×6.3%+7.7%
U.S. Physical Therapy USPHUnited States$1.42B+53%+10%10%29.4×18.8%+13.0%
H.U.Group 4544.TJapan$1.44B+24%+1%3%39.9×9.7%+2.1%
Teladoc Health TDOCUnited States$1.47B+24%-2%-5%n/a-6.4%+18.3%
agilon health AGLUnited States$1.52B+12%+2%-2%34.1×n/an/a
GeneDx WGSUnited States$1.56B+16%+15%-14%54.2×n/an/a
Novogene 688315.SSChina$1.01B+13%+6%7%44.8×13.9%+8.2%
AdaptHealth AHCOUnited States$1.01B-30%-3%3%n/a16.8%+25.2%
Ambea AMBEA.STSweden$1.59B+28%+11%9%15.2×1.1%+7.7%
Sonida Senior Living SNDAUnited States$1.59B-11%+70%-8%n/an/an/a
Personalis PSNLUnited States$1.62B+88%+17%-157%n/an/an/a
Regis Healthcare REG.AXAustralia$962M-28%+17%4%25.3×13.3%+14.4%
Vijaya Diagnostic Centre VIJAYA.NSIndia$1.69B+18%+24%32%63.0×40.4%+16.7%

Questions

Who are Pennant's main competitors?
Named competitors: Amedisys (private or unlisted), Addus HomeCare (ADUS), Brookdale Senior Living (BKD), Encompass Health (EHC). The cockpit's measured peer set (industry) also includes OPKO Health (OPK), Metropolis Healthcare (METROPOLIS.NS), Diagnostyka (DIA.WA), Clariane (CLARI.PA), Nutex Health (NUTX), Lumexa Imaging (LMRI).
Is Pennant expensive compared with its peers?
On forward p/e it trades at 23.7× against a peer median of 29.4×, 7th cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Pennant stock performed?
Over six months to 18 Nov 2026 the shares returned +1.4% against +17.1% for the median peer; over one year +41.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.